Related Jobs
-
Senior Clinical Research Associate
Job Type: Permanent
Salary: € 30000.00 per annum
Location: Croatia -
Drug Safety Physician
Job Type: Permanent
Salary: € 60000.00 per annum
Location: Netherlands
Novo Nordisk: Over 70% of diabetes patients reach target in study
10 Jun 2008
Clinical Research
Danish drugmaker Novo Nordisk has revealed that a total of 71 per cent of patients involved in the company's Improve study reached their target blood sugar levels.
According to the pharmaceutical company, the Improve clinical trial is the largest ever observational study of a diabetes drug and it was found that the company's NovoMix 30 significantly improved the control of blood sugar levels in patients with type 2 diabetes.
"While the number of people left with very high HbA1c levels before treatment with insulin is alarming, it is encouraging that treatment with NovoMix 30 was able to bring them in good control in just six months," said Professor Paul Valensi, head of the Department of Endocrinology-Diabetology-Nutrition at the Jean Verdier Hospital in France, and principal investigator of the study.
He added that the drug is "clearly an effective treatment option" for people with the condition who are unable to control it by other means.
The company has recently received approval from US regulators for its hemophilia treatment NovoSeven.
